Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Your Environment. Your Health.

Publication Detail

Title: Multiplexed relative and absolute quantitative immunopeptidomics reveals MHC I repertoire alterations induced by CDK4/6 inhibition.

Authors: Stopfer, Lauren E; Mesfin, Joshua M; Joughin, Brian A; Lauffenburger, Douglas A; White, Forest M

Published In Nat Commun, (2020 06 02)

Abstract: Peptides bound to class I major histocompatibility complexes (MHC) play a critical role in immune cell recognition and can trigger an antitumor immune response in cancer. Surface MHC levels can be modulated by anticancer agents, altering immunity. However, understanding the peptide repertoire's response to treatment remains challenging and is limited by quantitative mass spectrometry-based strategies lacking normalization controls. We describe an experimental platform that leverages recombinant heavy isotope-coded peptide MHCs (hipMHCs) and multiplex isotope tagging to quantify peptide repertoire alterations using low sample input. HipMHCs improve quantitative accuracy of peptide repertoire changes by normalizing for variation across analyses and enable absolute quantification using internal calibrants to determine copies per cell of MHC antigens, which can inform immunotherapy design. Applying this platform in melanoma cell lines to profile the immunopeptidome response to CDK4/6 inhibition and interferon-γ - known modulators of antigen presentation - uncovers treatment-specific alterations, connecting the intracellular response to extracellular immune presentation.

PubMed ID: 32488085 Exiting the NIEHS site

MeSH Terms: Antigen Presentation; Antigens; Cell Line; Cyclin-Dependent Kinase 4/metabolism*; Cyclin-Dependent Kinase 6/metabolism*; Histocompatibility Antigens Class I/immunology*; Histocompatibility Antigens Class I/metabolism*; Humans; Immunotherapy; Interferon-gamma/pharmacology; Mass Spectrometry; Peptides/immunology; Proteomics

to Top